ClinicalTrials.gg
Status unknownNCT01386853Updated Jul 1, 2011

Efficacy and Safety Study of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients

A Phase 3 interventional study of Pitavastatin and Atorvastatin in Hyperlipidemia, sponsored by Tai Tien Pharmaceuticals Co., Ltd.. Status unknown at 6 sites in Taiwan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-07-01.

Sponsored by Tai Tien Pharmaceuticals Co., Ltd. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2011), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Hyperlipidemias with a site in Taiwan — 9 open to participants now, 11 under way, 5 of them phase 3. Hyperlipidemias · Taiwan.

Planned enrollment
14th of 35
200 · median 120
Started
2011
with 2 others
Phase 3
21 of 40
3 open now
Registered
12th of 40
by date

Among the 40 studies in Hyperlipidemias with a site in Taiwan, this one is the 14th largest by planned enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2011, is one of 21 in phase 3, and was the 12th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

9 of the 40 studies in Hyperlipidemias with a site in Taiwan are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Hyperlipidemias with a site in Taiwan, or all of them as a file.
02

Study summary

This is a 12-week, randomized, multicenter, double-blind, active-controlled, non-inferiority study (TATPITA20101005) to compare the efficacy and safety of pitavastatin (Livalo®) and atorvastatin (Lipitor®) in high risk hypercholesterolemic patients.

03

Conditions studied

  • Hyperlipidemia

Browse trials for

Keywords

  • Hyperlipidemia
  • Pitavastatin
  • Atorvastatin
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged ≥ 20 years old and \< 75 years old.
  • Patient who was eligible and able to participate in the study and accepts to enter the study by signing written .
  • Patient with fasting LDL-C > 100 mg/dL. The concentration of LDL-C is obtained from laboratory examination.
  • Patient with at least one of the following description (NCEP ATP III guideline).
  • Female patient with must take reliable method(s) during the participation of the study.

Exclusion criteria

Exclusion Criteria:

  • Patient who has participated in other studies within 3 months.
  • Patient took medication and natural health foods known to alter blood lipid profiles within 4 weeks.
  • Patient is taking any medication or food that is prohibited by the study.
  • Patient taking Amiodarone will be excluded from this study (due to long half life of this medication).
  • Patient is diagnosed with type 1 DM or has been using insulin/insulin analog medication.
  • Patient with a history of multiple drug allergies or with a known allergy to HMG-CoA reductase inhibitors.
  • Patient with TG > 400 mg/dL.
  • Excessive obesity defined as above 35 kg/m2.
  • Cerebral vascular disease (including cerebrovascular hemorrhage or ischemia, ) diagnosed within 3 months.
  • Myocardial infarction, heart failure ( class III or IV), gross cardiac enlargement (cardiothoracic ratio > 0.5), significant heart block or cardiac arrhythmias within 3 months; history of uncontrolled complex ventricular arrhythmias, uncontrolled atrial fibrillation/flutter or uncontrolled supraventricular tachycardia, pacemaker or implantable cardiac device were not eligible for this study.
  • Patient with advanced renal disorder (Serum creatinine levels ≥ 2 mg/dL and BUN ≥ 25 mg/dL).
  • Patient with advanced hepatic disorder ( or ALT level ≥ 100 IU/L)
  • Patient with CK level > 5 × ULRR at any time point between Visit 1 and Visit 2.
  • Patient with poorly controlled diabetes mellitus ( > 9.0%) or patient with severe hypertension (> 180 mmHg for systolic or > 120 mmHg in diastolic blood pressure).
  • Patient with hypothyroidism, hereditary muscular disorders, family history of the above or history of drug-induced myopathy.
  • Patient has significant alcohol consumption (> 65 mL pure alcohol) within 48 hours before Visit 2.
  • Any major surgery within 3 months prior to Visit 2.
  • Female patient who is lactating, being pregnant or plans to become pregnant.
  • Patient with conditions judged by the investigator as unsuitable for the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Pitavastatin

    Drug: Pitavastatin

  • Active comparator
    Atorvastatin

    Drug: Atorvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. The change of LDL-C

    Time frame: Baseline to 12 weeks

Secondary outcomes

  1. The proportion of patients achieving LDL-C < 100 mg/dL; the changes of HDL-C, TG, non-HDL-C, Apo A1 and Apo B, fasting plasma glucose, fasting insulin level, insulin resistance by the HOMA-IR, HbA1c, free fatty acid, and ADMA

    Time frame: Baseline to 4 weeks and 12 weeks

07

Study locations

6 sites
  • Changhua Christian Hospital
    Chang-hua, Taiwan
    • Chien-Hsun Hsia, M.D. · Principal investigator
    • Lee-Shin Lin, M.D. · Sub investigator
  • National Cheng Kung University Hospital
    Tainan, Taiwan
    • Ping-Yen Liu, M.D. Ph.D. · Principal investigator
    • Po-Sheng Chen, M.D. · Sub investigator
    • Ju-Yi Chen, M.D. · Sub investigator
    • Wei-Ting Li, M.D. · Sub investigator
    • Yen-Wen Liu, M.D. · Sub investigator
    • Cheng-Han Lee, M.D. · Sub investigator
    • Wei-Chuan Tsai, M.D. · Sub investigator
    • Yi-Heng Li, M.D. · Sub investigator
    • Chih-Chan Lin, M.D. · Sub investigator
    • Shih-Hung Chan, M.D. · Sub investigator
    • Ting-Hsing Chao, M.D. · Sub investigator
  • Chang Gung Memorial Hospital-LinKou
    Taipei, Taiwan
    • Ming-Shien Wen, M.D. Ph.D. · Principal investigator
    • Kuo-Chun Hung, M.D. · Sub investigator
    • I-Chang Hsieh, M.D. · Sub investigator
    • Chao-Yung Wang, M.D. · Sub investigator
    • Chun-Chi Chen, M.D. · Sub investigator
  • National Taiwan University Hospital
    Taipei, Taiwan
    • Kuo-Liong Chien, M.D. Ph.D. · Principal investigator
    • Chia-Lun Chao, M.D. · Sub investigator
    • Ta-Chen Su, M.D. Ph.D. · Sub investigator
    • Hung-Ju Lin, M.D. · Sub investigator
  • Taipei Veterans General Hospital
    Taipei, Taiwan
    • Tao-Cheng Wu, M.D. Ph.D. · Principal investigator
    • Chin-Chou Huang, M.D. · Sub investigator
    • Liang-Yu Lin, M.D. · Sub investigator
    • Wen-Chung Yu, M.D. · Sub investigator
  • Tri-Service General Hospital
    Taipei, Taiwan
08

References and documents

Publications

  • Lin LY, Huang CC, Chen JS, Wu TC, Leu HB, Huang PH, Chang TT, Lin SJ, Chen JW. Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study. Cardiovasc Diabetol. 2014 Jul 16;13:111. doi: 10.1186/s12933-014-0111-1. PubMed 25027585 ↗
  • Liu PY, Lin LY, Lin HJ, Hsia CH, Hung YR, Yeh HI, Wu TC, Chen JY, Chien KL, Chen JW. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). PLoS One. 2013 Oct 1;8(10):e76298. doi: 10.1371/journal.pone.0076298. eCollection 2013. Erratum In: PLoS One. 2014;9(11):e114175. PubMed 24098467 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Mar 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2011
First posted
Jul 1, 2011
Start
Jul 2011
Primary completionEst.
Mar 2012
CompletionEst.
Jul 2012
Last update
Jul 1, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01386853
Lead sponsor
Tai Tien Pharmaceuticals Co., Ltd.
First posted
Jul 1, 2011
Start date
Jul 2011
Primary completion
Mar 2012 (estimated)
Completion
Jul 2012 (estimated)
Last update
Jul 1, 2011

Study contacts

Jasmine Chao
Contact
jasmine@tanabe.com.tw
+886-27423012
Jaw-Wen Chen, M.D. Ph.D.
principal investigator · Taipei Veterans General Hospital, Taipei, Taiwan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion